← Human Trials & Peer-Reviewed Studies
Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial.
Plain-language guide to PMID 40158795 (2025): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 32 participants.
Key Facts
- PMID
- 40158795
- Journal
- Metabolism: clinical and experimental
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Kawahara T et al. (8 authors)
- DOI
- 10.1016/j.metabol.2025.156240
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The muscle-building and strengthening effects of the active form of vitamin D in humans remain unclear.
Who Took Part
According to the abstract, 32 participants were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
The protein levels of molecules involved in muscle synthesis and degradation pathways were examined using western blotting.
Additionally, the skeletal muscle and body fat volumes were measured using bioelectrical impedance analysis with a body composition analyzer.
What Was Measured
The subject headings attached to it are Muscle, Skeletal, Sarcopenia, Vitamin D, Signal Transduction, Body Composition, Muscle Strength and TOR Serine-Threonine Kinases.
Author keywords: Active form of vitamin D, FOXO1, MuRF 1, Skeletal muscle and mTOR.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 32 participants.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (Metabolism: clinical and experimental), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.